64Cu-SARTATE clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses 64Cu-SARTATE is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2015 (1)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2018 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Clarity Pharmaceuticals Ltd (3)
Often tested with
Tested in the same studies.
Ucasareotide dasaroxetan CU-67 (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Studies
Open first, then newest update. How each study uses 64Cu-SARTATE is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)CompletedPhase 2Clarity Pharmaceuticals LtdNCT04438304Written as 64Cu-SARTATEHow we know
- An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine TumoursCompletedEarly Phase 1Clarity Pharmaceuticals LtdNCT04440956Written as 64Cu-SARTATEHow we know
- Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™CompletedPhase 1/2Clarity Pharmaceuticals LtdNCT03936426Written as Cu-64 SARTATE and Cu-67 SARTATEHow we know